Marc Abrams

CTO & Head of US Operations at SanegeneBio

Speaker

Marc has over 20 years' experience in discovery and development of genetic medicines, including RNAi and gene therapy. He started his career at Merck and Co. Inc., taking on roles of increasing responsibility in the early days of the field. More recently, Marc served as SVP, Discovery Research at Dicerna Pharmaceuticals (a Novo Nordisk Company) and as CSO of Carbon Biosciences. Marc is currently CTO & Head of US Operations at SanegeneBio, working on novel RNAi delivery strategies and target biology. His therapeutic area experience spans diverse indication spaces including oncology, antiviral and metabolic diseases. Marc has a Ph.D. in Biochemistry from Thomas Jefferson University.